Approved Medications Research

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

Cabenuva / By

“Treatment with long-acting (LA) ART may improve adherence and health-related quality of life. The objective of this study was to evaluate the cost-effectiveness of cabotegravir + rilpivirine (CAB+RPV) LA administered every 2 months (Q2M) compared with current ART administered as daily oral single-tablet regimens (STRs) from a Spanish National Healthcare System perspective. This study demonstrated […]

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain Read More »

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Cabenuva / By

Data support the use of long-acting cabotegravir plus rilpivirine dosed every 2 months as a complete antiretroviral regimen that has similar efficacy to a commonly used integrase strand transfer inhibitor-based first-line regimen while addressing unmet psychosocial issues associated with daily oral treatment.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial Read More »

Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a 1 rectal SHIV challenge macaque model

Lenacapavir / By

Pre-exposure prophylaxis (PrEP) using long-acting antiretroviral medications is a promising new HIV preventive method to daily oral regimens. A first-in-class long-acting capsid inhibitor called lenacapavir (LEN) has been licensed for the treatment of HIV-1 infection. In this study, the authors used a single high-dose simian-human immunodeficiency virus (SHIV) rectal challenge macaque 39 paradigms to evaluate

Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a 1 rectal SHIV challenge macaque model Read More »

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV

Lenacapavir / By

Incorporating LA ARVs and bNAbs into regimens has proven to be a challenging task. For the dosage schedules of the two medicines to work together, identical half-lives are required. Additionally, bNAb susceptibility testing is required to ensure that the bNAb is active in order to protect against the possibility of developing resistance to the LA

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV Read More »

High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda

Cabenuva / By

The HIV treatment approach known as long-acting injectable antiretroviral therapy (LAI ART), which includes a bimonthly injection of cabotegravir/rilpivirine, appears promising. People who are hesitant to start LAI ART or who adhere to it poorly and who are not virally suppressed may gain the most from it. However, the acceptability and viability of LAI ART

High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda Read More »

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Cabenuva / By

A full, long-acting (LA) regimen for maintaining HIV-1 virologic suppression consists of cabotegravir (CAB) and rilpivirine (RPV), administered intramuscularly monthly or every two months. In this report, the authors provide the findings from week 152 of the ATLAS-2M antiretroviral treatment research.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study Read More »

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis

Apretude / By

WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the compliance with daily oral TDF-FTC in real life is low. Long-acting cabotegravir is currently the only long-acting drug approved by

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis Read More »

Long-acting antiretrovirals and HIV treatment adherence

Cabenuva / By

Long-acting cabotegravir with rilpivirine ART has reduced the required dosing frequency from once daily to once every month or every two months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment.

Long-acting antiretrovirals and HIV treatment adherence Read More »

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition

Apretude / By

CAB-LA is highly efficacious for HIV prevention with few safety concerns. CAB-LA may lead to an increased risk of INSTI resistance among those who have acute HIV infection at initiation or become infected while taking CAB-LA. However, results are limited to controlled studies; more research is needed on real-world implementation.

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition Read More »

Scroll to Top